Capricor Therapeutics’ (CAPR) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald has reaffirmed its ‘overweight’ rating on Capricor Therapeutics (NASDAQ: CAPR). The brokerage set a $30 price target and estimated FY2025 earnings at $1.71 per share.
3 months ago
1 min read
